Aurealis Therapeutics raises $10 Million in an oversubscribed Series A financing to accelerate Phase 2 clinical studies in chronic wounds and preclinical development in oncology with its first-in-class technology platform
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to […]
Aurealis Therapeutics completes Phase 1 Last Patient Last Visit: After 12 months follow-up, no healed ulcer has recurred
Aurealis Therapeutics Phase 1 clinical study for non-healing Diabetic Foot Ulcers (DFUs) had its last patient last visit on March 20, 2023. We are incredibly happy to share while 83% of the patients receiving the lead therapeutic dose achieved complete healing, no healed ulcer has recurred after 12 months follow-up. This was the first clinical […]
Aurealis Therapeutics successfully completes treatment period of its AUP-16 Phase 1 study in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that it has successfully completed its Phase 1 study of its lead therapeutic candidate AUP-16 in non-healing Diabetic Foot Ulcers patients, both in terms of patient recruitment and treatment. While patient observation period continues, collected data will be processed and […]
Aurealis Therapeutics publishes first study on four-in-one -combination therapy using live lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the company successfully completed an […]
Aurealis Therapeutics to strengthen its Management Team by appointing Laurent Décory as Chief Operating Officer
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and Scientific […]
Aurealis Therapeutics Partner Xbiome Receives IND Approval from China’s National Medical Products Administration for the Phase 2 Study with AUP-16 in Diabetic Foot Ulcers
Xbiome announced that its Phase 2 study with AUP-16 (AUP1602-C) in diabetic foot ulcer has officially obtained IND approval from the National Medical Products Administration (NMPA) and the study can be initiated in China. Public information shows that AUP1602-C is the first genetically engineered bacterial drug product to obtain clinical approval from the NMPA, setting […]
Aurealis Therapeutics and Xbiome enter into a license and collaboration agreement for Aurealis four-in-one diabetic foot ulcer and inflammatory disease cell and gene therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease […]
Aurealis Therapeutics successfully completes low therapeutic dose cohort of AUP-16 Phase 1 DFU trial, advances to medium therapeutic dose group
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation […]
Aurealis Therapeutics has initiated repeated dosing groups in the AUP-16 Phase 1 Diabetic Foot Ulcer clinical trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved dressings and devices. The company announced today that […]
Aurealis Therapeutics to strengthen its Board of Directors by appointing Laurent Décory
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin and Roger Meier were elected to continue along […]
